BlueRock Therapeutics said it has built an automated system for high-throughput auditing of cell therapies, designed to work with small sample volumes and the workflows typical in cell manufacturing. The company described an analytics platform that handles liquid handling and processing for cell-culture-based material, aiming to close a gap in scalable QC and analytical review tooling for cell therapy. BlueRock said the system was developed in collaboration with Hamilton Robotics, adapting existing analytical systems to new modality constraints posed by cell-therapy manufacturing economics. The company framed the initiative as a way to help reduce the cost of analytics and shorten time-to-market by shrinking sample and reagent requirements. The company indicated it expects the technology to scale toward commercial volumes and that the approach could be adapted beyond BlueRock’s own programs. Industry observers may view the announcement as part of a broader push to systematize cell-therapy quality work—especially as manufacturing models evolve from pilot lots into larger, repeatable supply chains.